Sanofi lowered to Neutral at UBS on lack of catalysts, lower growth

Aug. 09, 2022 3:35 PM ETSanofi (SNY)SNYNF, GCVRZBy: Dulan Lokuwithana, SA News Editor5 Comments

Sanofi Distribution Centre in Kirkland, Quebec, Canada.

JHVEPhoto/iStock Editorial via Getty Images

  • UBS downgraded the French drugmaker Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRZ) to Neutral from Buy on Tuesday, citing a potential slowdown and lack of catalysts for the remainder of the year.
  • Noting that key development programs

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.